JERUSALEM, Jan 29 (Reuters) - Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit sales gains in a trio of its branded drugs to treat migraines, Huntington's disease and schizophrenia.
The world's largest generic drugmaker said on Wednesday it earned 71 cents per diluted share excluding one-time items in the October-December quarter, down from $1.00 per share a year earlier. Revenue fell 5% to $4.2 billion.
Analysts had forecast earnings of 70 cents per share ex-items for the Israel-based company on revenue of $4.13 billion, LSEG I/B/E/S data showed.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。